Dabur India Clarifies USFDA Observations on Silvassa Plant; States No Financial or Operational Impact
Dabur India Ltd has issued a clarification addressing recent reports in the mainstream media concerning observations made by the United States Food & Drug Administration (USFDA). The company addressed news appearing on May 29, 2026, and May 30, 2026, providing details regarding the scope of the findings and its ongoing corrective actions.The company confirmed that the observations provided by the USFDA relate to only a small segment of its manufacturing plant located at Silvassa, Dadra and Nagar Haveli. Dabur India stated that this specific plant generates insignificant revenue for the business.
Despite the audit findings, Dabur India confirmed that the manufacturing plant remains fully operational. The company is actively engaged with the USFDA regarding the audit findings and has developed a robust corrective and preventive action plan. Updates on this plan have been regularly shared with the USFDA.
Dabur India emphasized its continuous commitment to quality, assuring that it implements strong controls to ensure that its quality systems are never compromised. The company reiterated its dedication to maintaining the highest standards of product quality across all its manufacturing operations and sites.
In addressing the broader impact, Dabur India stated that, as of now, there is no impact on the financial, operational, or other activities of the company due to the USFDA findings.
The company also affirmed that all its products are manufactured and delivered with the highest level of quality and hygiene, in strict compliance with applicable regulations, standards, and specifications. Dabur India maintains that it is committed to complying with all regulatory requirements.
DABUR Stock Price Movement
As of 2:50 PM, shares of Dabur India Limited are slipping by 3.77% in live trading, currently priced at ₹426.70. The stock movement is occurring amidst strong liquidity, with over 2.38 million shares traded in the market so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.